Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Fierce BioTech

MAY 2, 2024

West Pharmaceutical Services (West) and Cytiva have teamed up to offer innovative and versatile fill finish solutions to efficiently meet the unique demands of advanced pharmaceutical applications. In this webinar, you will learn about: The challenges and risks related to the packaging and filling of high-value drug products.

Therapies 52

Therapies Packaging Pharmaceuticals Production 52

BioPharma Drive: Drug Pricing

OCTOBER 21, 2024

Immunotherapy and precision medicine show promise in better fighting cancer. What else does the research tell us?

Research 103

Research Therapies Pharmaceuticals 103

BioPharma Drive: Drug Pricing

DECEMBER 8, 2023

In addition to clearing Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, the FDA also granted an early OK to Bluebird bio’s sickle cell treatment Lyfgenia.

FDA 139

FDA Therapies Pharmaceuticals Treatment 139

Drug Target Review

JULY 11, 2024

To date, there are less than 30 known surface proteins that form the basis of all approved cancer-targeted therapies of all modalities, including antibody-drug conjugates (ADCs), T-cell engagers, CAR T-cells and radiopharmaceuticals. These could be targets for antibody-drug conjugates (ADCs), bi-specific antibodies, or other therapies.

Therapies 56

Therapies RNA Pharma Companies Disease 56

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Drug Target Review

FEBRUARY 1, 2024

Historically, what has limited investor interest in funding neurological and psychiatric therapies in development? Investors have historically taken a ‘guilty until proven innocent’ approach to investing in neuroscience therapies. We were able to license a molecule from a multi-national pharmaceutical company.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

thought leadership

NOVEMBER 7, 2024

These programs vary based on the therapeutic area and specific medications but share the common objective of assisting patients in overcoming barriers to therapy access and adherence, ultimately enhancing their health outcomes.

Clinical Trials 98

Clinical Trials Therapies Pharmaceuticals Trials 98

Drug Discovery Today

JULY 30, 2020

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Therapies 100

Therapies Pharmaceuticals Disease 100

BioPharma Drive: Drug Pricing

AUGUST 16, 2023

The decision stands in contrast to the agency’s plans for a would-be rival gene editing treatment from Vertex Pharmaceuticals and CRISPR Therapeutics that is also under a regulatory review.

Therapies 98

Therapies FDA Pharmaceuticals Treatment 98

BioPharma Drive: Drug Pricing

DECEMBER 10, 2023

A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. This is the story of how it came to be.

Therapies 142

Therapies Pharmaceuticals Disease 142

SCIENMAG: Medicine & Health

OCTOBER 26, 2023

A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. Credit: Dwight Andrews/UTHealth Houston A four-year, $3.4

Research 52

Research Therapies Pharmaceuticals Treatment 52

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., ” “We are delighted to partner with Bayer in the area of gene therapy. .” ” “We are delighted to partner with Bayer in the area of gene therapy.

Therapies 40

Therapies RNA Licensing Licensing 40

BioPharma Drive: Drug Pricing

NOVEMBER 8, 2023

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

Therapies 130

Therapies Pharmaceuticals Treatment Disease 130

The Pharma Data

FEBRUARY 24, 2022

Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022 Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases. senior vice president, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “BI

Therapies 52

Therapies FDA Clinical Trials Disease 52

Crown Bioscience

NOVEMBER 11, 2024

The use of biomarkers has transformed the pharmaceutical industry by allowing researchers to develop therapies that target specific pathways in diseases. These can be proteins, genes, or other molecules that signal an abnormal or normal process in the body.

Drug Development 52

Drug Development Drugs Therapies Pharmaceuticals 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. In an interview with BioSpace, De Backer outlined Bayer’s thought process for opening its purse strings and diving into the deep end of the cell and gene therapy space. Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners.

Pharmaceuticals 74

Pharmaceuticals Therapies Production Drugs 74

Drug Target Review

OCTOBER 28, 2024

My scientific background, technical understanding and analytical thinking continue to help me be successful in taking on roles with increased business responsibilities, such as my current role overseeing the global therapy innovations business unit at Terumo BCT. The advancements in cell and gene therapy are really very exciting.

Engineering 96

Engineering Therapies Treatment Disease 96

The Pharma Data

MARCH 13, 2022

NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Pfizer Inc. Pfizer Inc.:

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

The Pharma Data

MARCH 31, 2022

Bayer announced today that it is strengthening the production network of its pharmaceutical division to ensure sustainable competitiveness and support the transformation of its pharmaceutical business based on breakthrough innovation delivering long-term, sustainable business growth.

Production 52

Production Pharmaceuticals Science Therapies 52

Chemical Biology and Drug Design

JUNE 19, 2024

Exploring the transformative impact of large language models (LLMs) in molecular biology and drug development, discussing potential areas of applications and breakthroughs in personalized therapies. While enhancing molecular biology aspects, we also address ethical concerns ensuring responsible application of these models.

Molecular Biology 100

Molecular Biology Drug Development Drugs Therapies 100

Drug Target Review

AUGUST 6, 2024

Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis. Expedited programs like the FDA’s Breakthrough Therapy Designation and Fast Track can shorten development timelines and reduce risk. CDMOs are crucial.

Therapies 117

Therapies Pharmaceutical Companies Disease Treatment 117

Chemical Biology and Drug Design

SEPTEMBER 13, 2023

This review aims to provide information on cutting-edge Nano particulate-based technologies and Nano therapies for colorectal cancer. The field of cancer detection and therapy has undergone a revolution with the development of nanotechnology for targeted drug delivery.

Drugs 100

Drugs Therapies Science Pharmaceuticals 100

Drug Target Review

NOVEMBER 27, 2023

By directly interfering with the eIF4F complex, eFFECTOR’s STRIs provide a promising avenue for disrupting the core mechanisms of cancer, offering the potential to improve patient outcomes and overcome the limitations of traditional cancer therapies. Prior to Anadys Pharmaceuticals, Inc., Prior to Anadys Pharmaceuticals, Inc.,

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

Drug Hunter

SEPTEMBER 17, 2023

This month features many of the big reveals from the ACS fall 2023 first disclosures including Nurix’s BTK degrader and RAPT’s CCR4 autoimmune therapy. selective inhibitor developed by Vertex Pharmaceuticals for acute pain in Phase III clinical trials. Several of the molecules making the August list are in Ph.

Clinical Trials 206

Clinical Trials Trials Therapies Pharmaceuticals 206

BioPharma Drive: Drug Pricing

JUNE 4, 2024

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

Therapies 67

Therapies Pharmaceuticals Trials Treatment 67

The Pharma Data

JUNE 2, 2022

New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo ® with Bristol Myers Squibb’s technologies and oncology drug development expertise. Chief Executive Officer and Co-Founder of Immatics. “We FRCP, D.Phil., About ACTallo ®.

Therapies 52

Therapies Production Engineering Clinical Development 52

The Pharma Data

APRIL 19, 2022

Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies. — Scalable and Adaptable Facility Provides Flexibility for Current and Future Cell Therapy Innovation. The site will produce Kite’s FDA approved CAR T-cell therapy used to treat blood cancer.

FDA Approval 52

FDA Approval Therapies FDA Hospitals 52

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 71

Drug Development Metabolic Stability Clinical Trials Drugs 71

LifeSciVC

OCTOBER 13, 2022

This summer, approvals on both sides of the Atlantic – for beta thalassemia and cerebral adrenoleukodystrophy in the United States and for severe hemophilia A and aromatic L-amino acid carboxylase deficiency in Europe – show that regulators are likely open to green-lighting a range of emerging gene therapies.

Therapies 40

Therapies Disease Treatment Marketing 40

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. An example is the collaboration between Novartis and the University of Oxford to develop a gene therapy for spinal muscular atrophy, a rare genetic disease.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. This designation for gantenerumab marks the 39th Breakthrough Therapy Designation for Roche’s portfolio of medicines.

Therapies 52

Therapies Disease FDA Trials 52

The Pharma Data

MAY 27, 2022

of patients with RRMM responding to therapy (98 percent overall response rate ORR ).1,6 “The approval of Janssen’s first cell therapy is testament to our ongoing commitment to advance science and transform outcomes for those living with multiple myeloma,” said Sen Zhuang, M.D., In December 2017, Janssen Biotech, Inc.

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. CARLSBAD, Calif. ,

Therapies 52

Therapies Clinical Trials Science Laboratories 52